Heart Failure Patient Conversion From LVAD To TAH Debated By Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices Panel has left the door open for cardiac surgeons to use SynCardia's CardioWest Total Artificial Heart (TAH) in transplant candidates who fail left ventricular assist device (LVAD) therapy
You may also be interested in...
SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel
SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel
SynCardia Plans U.S. Equivalency Trial Of Portable Total Artificial Heart
SynCardia's CardioWest Total Artificial Heart could be used in up to 500 U.S. cardiac transplant candidates annually, according to the firm